- £303.60m
- £37.64m
- $4.83m
- 51
- 60
- 56
- 57
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1 | ||
| Price to Tang. Book | 1.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 86.24 | ||
| EV to EBITDA | 2.65 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.84% | ||
| Return on Equity | 12.18% | ||
| Operating Margin | 329.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 11.77 | 17.39 | 15.62 | 3.33 | 4.83 | n/a | n/a | -13.21% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
Directors
- Christopher Viehbacher NEC (61)
- Bharatt Chowrira PRE (55)
- Daphne Zohar CEO (52)
- Robert Langer CFD
- George Farmer CFO
- Joep Muijrers CEX
- Joseph Bolen CSO (66)
- Eric Elenko OTH
- Julie Krop OTH (54)
- Alison Bauerlein DRC
- Matthew Patterson DRC (48)
- Jane Wildman DRC
- Raju Kucherlapati NID (77)
- John Lamattina NID (71)
- Kiran Mazumdar-Shaw NID (68)
- Marjorie Scardino NID (77)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 8th, 2015
- Public Since
- June 19th, 2015
- No. of Employees
- 56
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 240,189,449
- Address
- 6 Tide Street, Suite 400, BOSTON, 02210
- Web
- https://puretechhealth.com/
- Phone
- +1 6174822333
- Auditors
- PricewaterhouseCoopers LLP
Latest News for PRTC
Upcoming Events for PRTC
Half Year 2025 PureTech Health PLC Earnings Release
Similar to PRTC
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 22:47 UTC, shares in Puretech Health are trading at 126.40p. This share price information is delayed by 15 minutes.
Shares in Puretech Health last closed at 126.40p and the price had moved by -32.69% over the past 365 days. In terms of relative price strength the Puretech Health share price has underperformed the FTSE All Share Index by -37.49% over the past year.
The overall consensus recommendation for Puretech Health is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePuretech Health does not currently pay a dividend.
Puretech Health does not currently pay a dividend.
Puretech Health does not currently pay a dividend.
To buy shares in Puretech Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 126.40p, shares in Puretech Health had a market capitalisation of £303.60m.
Here are the trading details for Puretech Health:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: PRTC
Based on an overall assessment of its quality, value and momentum Puretech Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Puretech Health is 479.80p. That is 279.59% above the last closing price of 126.40p.
Analysts covering Puretech Health currently have a consensus Earnings Per Share (EPS) forecast of -$0.60 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Puretech Health. Over the past six months, its share price has underperformed the FTSE All Share Index by -23.52%.
As of the last closing price of 126.40p, shares in Puretech Health were trading -12.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Puretech Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 126.40p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Puretech Health's management team is headed by:
- Christopher Viehbacher - NEC
- Bharatt Chowrira - PRE
- Daphne Zohar - CEO
- Robert Langer - CFD
- George Farmer - CFO
- Joep Muijrers - CEX
- Joseph Bolen - CSO
- Eric Elenko - OTH
- Julie Krop - OTH
- Alison Bauerlein - DRC
- Matthew Patterson - DRC
- Jane Wildman - DRC
- Raju Kucherlapati - NID
- John Lamattina - NID
- Kiran Mazumdar-Shaw - NID
- Marjorie Scardino - NID